Monte Rosa Therapeutics/$GLUE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
- Ticker
- $GLUE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 185
- Headquarters
- Boston, United States
- Website
- www.monterosatx.com
GLUE Metrics
BasicAdvanced
$796M
-
-$1.35
1.38
-
Price and volume
Market cap
$796M
Beta
1.38
52-week high
$25.77
52-week low
$9.28
Average daily volume
1.5M
Financial strength
Current ratio
10.316
Quick ratio
10.24
Long term debt to equity
0.065
Total debt to equity
0.073
Profitability
EBITDA (TTM)
-142.643
Gross margin (TTM)
-92.15%
Net profit margin (TTM)
-186.24%
Operating margin (TTM)
-214.46%
Effective tax rate (TTM)
-0.80%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-16.29%
Return on equity (TTM)
-35.30%
Valuation
Price to revenue (TTM)
12.865
Price to book
1.6
Price to tangible book (TTM)
1.6
Price to free cash flow (TTM)
-5.188
Free cash flow yield (TTM)
-19.27%
Free cash flow per share (TTM)
-1.794
Growth
Revenue change (TTM)
-61.26%
Earnings per share change (TTM)
-633.94%
3-year earnings per share growth (CAGR)
-20.59%
What the Analysts think about GLUE
Analyst ratings (Buy, Hold, Sell) for Monte Rosa Therapeutics stock.
Analyst projections of the future price of Monte Rosa Therapeutics stock.
Bulls say / Bears say
In a 108-person Phase 1 study, MRT-8102 achieved 80–90% NEK7 degradation and reduced several inflammation markers, with no serious adverse events reported. That gives the programme a promising early biological and safety signal, although it is not yet proof of patient benefit. (Monte Rosa Therapeutics)
Novartis has started a second Phase 2 study of MRT-6160, triggering a $37.5 million milestone payment to Monte Rosa; it is also funding and running the Phase 2 work. This advances a partnered programme while limiting Monte Rosa’s near-term trial costs. (Monte Rosa Therapeutics)
In early MRT-2359 data, all five evaluable patients with androgen-receptor mutations had PSA responses, and two had partial responses on scans. Monte Rosa has since activated a Phase 2 study to test the signal in a larger group. (Monte Rosa Therapeutics)
MRT-8102’s encouraging Phase 1 results were based on four weeks of treatment and changes in biomarkers, not evidence that it prevents heart attacks or improves symptoms. The key efficacy question therefore remains unanswered. (Monte Rosa Therapeutics)
The planned six-month Phase 2b study of MRT-8102 depends on regulatory feedback and completion of long-term preclinical safety studies, and is now expected to start in the first half of 2027. Those requirements could slow the programme and defer more meaningful evidence of benefit. (SEC)
Monte Rosa remains loss-making: second-quarter collaboration revenue fell to $9.0 million from $23.2 million a year earlier, while R&D spending rose and its net loss widened to $43.4 million. Its stated cash runway into 2029 helps, but sustained development spending leaves the business reliant on partner payments and its cash reserves. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
GLUE Financial Performance
Revenues and expenses
GLUE Earnings Performance
Company profitability
Upcoming events
No upcoming events
GLUE News
AllArticlesVideos
Funds containing GLUE
Fund name | Fund size | $GLUE weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.05% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.